Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pharmaceutical Spending Fell Slightly; A First, Says IMS Institute

This article was originally published in The Pink Sheet Daily

Executive Summary

IMS report on U.S. medical trends highlights the trends in patient spending and shows that over one-third of spending was concentrated in the top five therapeutic classes in 2012.

You may also be interested in...



U.S. Drug Sales Top $329 Billion In 2013, Up 3.2% – IMS Report

IMS Health’s report on U.S. drug spending in 2013 shows a return to growth last year after a decline in 2012, with a lower impact of brands losing patent protection being an important factor, as well as brand price increases.

Early Drug Launches Off To a Strong Start So Far in 2013

2012 was a record year for drug approvals; now many of those drugs approved last year and this year are launching and off to a strong start in the first three months of 2013.

First-Cycle Approval Rate Already High; Can PDUFA V Actually Boost It?

FDA official says the rate of approving applications in the first review cycle may not increase much more, even as the new review model, intended to promote more first-cycle approvals, has yet to finish with its inaugural applications.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS075797

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel